A shrinkage approach for estimating a treatment effect using intermediate biomarker data in clinical trials
From MaRDI portal
Publication:2893404
DOI10.1111/J.1541-0420.2011.01608.XzbMATH Open1274.62818OpenAlexW2081091982WikidataQ33917331 ScholiaQ33917331MaRDI QIDQ2893404FDOQ2893404
Authors: Yun Li, Roderick Little, Jeremy M. G. Taylor 
Publication date: 20 June 2012
Published in: Biometrics (Search for Journal in Brave)
Full work available at URL: http://europepmc.org/articles/pmc3365575
Recommendations
- Model-free approach to quantifying the proportion of treatment effect explained by a surrogate marker
- Evaluation of longitudinal surrogate markers
- A Bayesian approach to surrogacy assessment using principal stratification in clinical trials
- A Measure of the Proportion of Treatment Effect Explained by a Surrogate Marker
- On Assessing Surrogacy in a Single Trial Setting Using a Semicompeting Risks Paradigm
Cites Work
- Adjusting for Nonignorable Drop-Out Using Semiparametric Nonresponse Models
- A Generalization of Sampling Without Replacement From a Finite Universe
- A Measure of the Proportion of Treatment Effect Explained by a Surrogate Marker
- Criteria for the Validation of Surrogate Endpoints in Randomized Experiments
- Survival analysis using auxiliary variables via multiple imputation, with application to AIDS clinical trial data
- The validation of surrogate endpoints in meta-analyses of randomized experiments
- Nonparametric Survival Estimation Using Prognostic Longitudinal Covariates
- Some comments on efficiency gains from auxiliary information for right-censored data
- Properties of A Nonparametric Test for Early Comparison of Treatments in Clinical Trials in the Presence of Surrogate Endpoints
Cited In (3)
This page was built for publication: A shrinkage approach for estimating a treatment effect using intermediate biomarker data in clinical trials
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q2893404)
